Eckert & Ziegler stock (DE0005659700): Q1 sales up 7% to €72.9M

Eckert & Ziegler reported Q1 2026 sales of €72.9 million, a 7% rise year-over-year, with net income at €10.4 million and confirmed full-year guidance, according to company data.

Eckert & Ziegler kicked off 2026 with strong quarterly results, posting Q1 sales of €72.9 million, up 7% from €68.2 million in the prior-year period. Net income reached €10.4 million, while EBIT before special items stood at €16.0 million. The medical segment drove growth amid sustained radiopharmaceutical demand, per the company's announcement as of May 2026 via MarketScreener as of 05/2026 and WebDisclosure as of 05/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eckert & Ziegler
• Sector/industry: Nuclear medicine and radiopharmaceuticals
• Headquarters/country: Germany
• Core markets: Europe, US, Asia
• Key revenue drivers: Radiopharmaceuticals, therapy equipment
• Home exchange/listing venue: Frankfurt (EZA.DE)
• Trading currency: EUR

Eckert & Ziegler: core business model

Eckert & Ziegler develops, produces, and distributes isotope-related products and radiation protection solutions for medical and scientific applications. The company serves nuclear medicine facilities, research institutions, and industrial clients worldwide with generators, cyclotrons, and shielding equipment for oncology diagnostics and therapy, according to its website and Ad-hoc-news.de as of 05/2026.

Listed on the Frankfurt Stock Exchange under ticker EZA.DE (ISIN DE0005659700), the firm focuses on the full value chain from radionuclides to finished radiopharmaceuticals, including theranostics that combine diagnostics and therapy.

Main revenue and product drivers for Eckert & Ziegler

Revenue primarily comes from the Pharma & Healthcare segment (radiopharmaceuticals like molybdenum-99/technetium-99m generators and iodine-131), Medical Technology (therapy equipment), and Industrial & Research. Q1 2026 sales growth was fueled by medical segment strength, with full-year 2026 forecast confirmed, per MarketScreener as of 05/2026.

A MarketsandMarkets report from 2025 projects Europe's nuclear medicine market growth at 20.2% CAGR for therapeutics through 2030, positioning Eckert & Ziegler for expansion in radioisotopes, as noted in Ad-hoc-news.de as of 05/2026 (report published 2025).

Industry trends and competitive position

Europe's nuclear medicine market is expanding due to aging populations, rising cancer rates, and demand for radiotherapeutics. Eckert & Ziegler is identified as an emerging leader, with production sites in Germany, the US, and France supporting global reach, per market analysis cited in recent reports.

Why Eckert & Ziegler matters for US investors

US retail investors can access Eckert & Ziegler via OTC trading or Frankfurt-listed shares, gaining exposure to Europe's radiopharma growth amid US market parallels in oncology treatments. The company's US production site enhances relevance to American healthcare trends, as highlighted in Ad-hoc-news.de as of 05/2026.

Conclusion

Eckert & Ziegler's Q1 2026 results show resilient growth in a promising sector, with sales up 7% and guidance intact. The company's positioning in nuclear medicine offers exposure to therapeutic demand trends. Investors should monitor upcoming quarters for sustained momentum amid market expansion.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.